Geneva — At the 5th WHO Pharmaceutical Pricing and Reimbursement Policies conference today, Doctors Without Borders presented the costs of its landmark TB-PRACTECAL clinical trial that helped identify a shorter, all-oral treatment regimen for drug-resistant tuberculosis ,* which totalled €34 million.
“We hope that our disclosure of clinical trial costs for identifying an improved regimen for drug-resistant tuberculosis will serve as a clarion call for other public and non-profit actors to join us and publicly share their clinical trial costs to ensure broader transparency in medical R&D costs,” said Dr Bern-Thomas Nyang’wa, MSF medical director and chief investigator of the TB-PRACTECAL trial.
For more than a decade, the critical TB drug bedaquiline, which is the backbone of all DR-TB regimens, including the TB-PRACTECAL regimen, remained out of reach for people with DR-TB due to its exorbitant price.
“As the World Health Assembly this year will mark the 5th year since the adoption of the transparency resolution, all governments must take urgent steps to enact legislation to mandate the disclosure of disaggregated R&D costs, including clinical trial costs, especially where the R&D received public funding,” said Scourse.
Law Law Latest News, Law Law Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: allafrica - 🏆 1. / 99 Read more »